Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Development of Histone Methylation Inhibitor DZNep Analogues for Anti-cancer Therapy
Exploit Technologies Pte Ltd Singapore flag Singapore
Abstract ID:
DZNep, a S-adenosylhomocysteine hydrolase (SAHH) inhibitor that is also a histone methylation inhibitor, has been shown to possess anti-cancer effects by selectively inducing apoptosis in cancer and transformed cells but not in normal cells....
Contact
Participants
You
Email me a copy of this message

As cancer is one of the leading causes of death worldwide, the need for compounds to induce apoptosis in cancer cells becomes prominent. Previous technologies have had limited applications in that they target few cancers. Other challenges include finding a way to induce apoptosis in cancer cells but not normal cells. This technology addresses those needs by providing a safe way to induce apoptosis in only cancer and transformed cells.


Our Innovation


DZNep, a S-adenosylhomocysteine hydrolase (SAHH) inhibitor that is also a histone methylation inhibitor, has been shown to possess anti-cancer effects by selectively inducing apoptosis in cancer and transformed cells but not in normal cells. It accomplishes this by the following:


Depleting the PRC2 complex (EZH2 complex), which has been shown to promote cell proliferation, invasion and metastasis in multiple human cancers.


Combining with TSA to induce DACT3 and abrogate Dvl2-Wnt/-catenin signaling.


Combining with HDAC inhibitor to reverse oncogenic reprogramming.

Type of Business Relationship Sought

Licensing, Co-Development, Start Up Company.

FEATURED
Last Updated Oct 2014
Technology Type
Phase of Development EARLY STAGE
CORPORATION